Search Videos and More
News
New Clinical Tool for Clonal Hematopoiesis Identifies Patients at High Risk for Blood Cancer
A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression.
News
Immunotherapy – Targeted Drug Combination Improves Survival in Advanced Kidney Cancer
The data presented here align with the initial results of the primary analysis of the CLEAR trial. This supports the use of lenvatinib plus pembrolizumab as a standard-of-care first-line treatment for patients with renal cell carcinoma.
News
Seeking Signs of Synergy: The Origins of PARP and PI3K Inhibitors
Pairing multiple drugs together to synergistically destroy a patient's tumor has become a common approach to cancer treatment
Symposium
2023 ASPHO Conference
Dana-Farber/Boston Children's Cancer and Blood Disorders Center offers the combined expertise of both a world class cancer center and an internationally renowned children’s hospital to provide seamless, integrated care for children with all types of cancer and blood disorders — including the rarest and most complex cases.
News
Dana-Farber Research Publication 05.01.2023
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Course
10th Annual Cancer Disparities Research Symposium
Dana-Farber Cancer Institute's Christopher Lathan, MD, MS, MPH, and Dana-Farber/Harvard Cancer Center's Karen Burns White host the Annual Cancer Disparities Research Symposium in recognition of National Minority Cancer Awareness.
News
High Concentrations of Immune Cells Within Tumors Associated with Longer Patient Survival
ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies
News
Clinical Trial Shows That Adding Bevacizumab to Targeted Drug and Chemotherapy Produces Striking Activity Against HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
Long-term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma
News
William Hahn is a 2023 Award of Excellence Honoree by Hope Funds
William Hahn, MD, PhD, executive vice president and chief operating officer at Dana-Farber Cancer Institute, is one of three exceptional individuals honored by Hope Funds with its 2023 Award of Excellence in the areas of Basic Science and Medicine.
Podcast
Season 2, Episode 4: Making it Personal: Targeted Cancer Therapies
By the early 2000s, researchers at Dana-Farber and elsewhere knew that a certain protein appeared in many tumors taken from lung cancer patients. Based on that data, doctors started treating those patients with a drug that inhibited that protein.
Podcast
Season 2, Episode 3: Stop the Division: CDK-4/6 Inhibitors and the Cell Cycle
Cancer is often a problem of cell division; cancer cells keep doubling and doubling, faster and faster.
Symposium
2023 ASCO GU Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the clinical updates you need to know from ASCO GU 2023.